Paratek Pharmaceuticals, Inc. - FORM 10-K - EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - March 30, 2010

Attached files

file filename
10-K - FORM 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2009 - Paratek Pharmaceuticals, Inc.d10k.htm
EX-31.2 - CERTIFICATION OF THE COMPANY'S CFO PURSUANT TO SECTION 302 - Paratek Pharmaceuticals, Inc.dex312.htm
EX-31.1 - CERTIFICATION OF THE COMPANY'S CEO PURSUANT TO SECTION 302 - Paratek Pharmaceuticals, Inc.dex311.htm
EX-21.1 - SUBSIDARIES OF THE REGISTRANT - Paratek Pharmaceuticals, Inc.dex211.htm
EX-32.1 - CERTIFICATION OF THE COMPANY'S CEO AND CFO PURSUANT TO SECTION 906 - Paratek Pharmaceuticals, Inc.dex321.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

 

  (1) Registration Statement (Form S-8 No. 333-135506) pertaining to the Novacea, Inc. 2006 Incentive Award Plan and the Amended 2001 Stock Option Plan of Novacea, Inc.;

 

  (2) Registration Statement (Form S-8 No. 333-150869) pertaining to the Novacea, Inc. 2006 Incentive Award Plan;

 

  (3) Registration Statement (Form S-8 No. 333-157927) pertaining to the Transcept Pharmaceuticals, Inc. 2006 Incentive Award Plan;

 

  (4) Registration Statement (Form S-8 No. 333-157929) pertaining to the Transcept Pharmaceuticals, Inc. Amended and Restated 2002 Stock Option Plan;

 

  (5) Registration Statement (Form S-8 No. 333-160222) pertaining to the Transcept Pharmaceuticals, Inc. 2009 Employee Stock Purchase Plan;

 

  (6) Registration Statement (Form S-8 No. 333-164468) pertaining to the Transcept Pharmaceuticals, Inc. 2006 Incentive Award Plan; and

 

  (7) Registration Statement (Form S-3 No. 333-145840) and related Prospectus of Novacea, Inc.;

of our report dated March 30, 2010, with respect to the consolidated financial statements of Transcept Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) of Transcept Pharmaceuticals, Inc. for the year ended December 31, 2009.

/s/ Ernst & Young LLP

Palo Alto, California

March 30, 2010

Paratek Pharmaceuticals, Inc. Reports

Also read